Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;33(6):669-674.
doi: 10.1007/s10557-019-06914-9.

The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart

Mitchel Tate  1   2 , Gavin C Higgins  2   3 , Miles J De Blasio  1 , Runa Lindblom  2   3 , Darnel Prakoso  1 , Minh Deo  1 , Helen Kiriazis  4 , Min Park  5 , Carlos D Baeza-Garza  5 , Stuart T Caldwell  6 , Richard C Hartley  6 , Thomas Krieg  5 , Michael P Murphy  5   7 , Melinda T Coughlan  2   3 , Rebecca H Ritchie  8   9
Affiliations

The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart

Mitchel Tate et al. Cardiovasc Drugs Ther. 2019 Dec.

Erratum in

Abstract

Purpose: Methylglyoxal, a by-product of glycolysis and a precursor in the formation of advanced glycation end-products, is significantly elevated in the diabetic myocardium. Therefore, we sought to investigate the mitochondria-targeted methylglyoxal scavenger, MitoGamide, in an experimental model of spontaneous diabetic cardiomyopathy.

Methods: Male 6-week-old Akita or wild type mice received daily oral gavage of MitoGamide or vehicle for 10 weeks. Several morphological and systemic parameters were assessed, as well as cardiac function by echocardiography.

Results: Akita mice were smaller in size than wild type counterparts in terms of body weight and tibial length. Akita mice exhibited elevated blood glucose and glycated haemoglobin. Total heart and individual ventricles were all smaller in Akita mice. None of the aforementioned parameters was impacted by MitoGamide treatment. Echocardiographic analysis confirmed that cardiac dimensions were smaller in Akita hearts. Diastolic dysfunction was evident in Akita mice, and notably, MitoGamide treatment preferentially improved several of these markers, including e'/a' ratio and E/e' ratio.

Conclusions: Our findings suggest that MitoGamide, a novel mitochondria-targeted approach, offers cardioprotection in experimental diabetes and therefore may offer therapeutic potential for the treatment of cardiomyopathy in patients with diabetes.

Keywords: Diabetes; Diabetic cardiomyopathy; Heart; Methylglyoxal.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. However, MPM and RCH declare that they are inventors on a patent that includes MitoGamide: Mitochondria-targeted dicarbonyl sequestering compounds. Murphy, M. P.; Smith, R.A. J.; Hartley, R. C. WO 2015075200. A1.

Figures

Fig. 1
Fig. 1
MitoGamide treatment attenuates LV diastolic dysfunction in Akita mice. a The structure of MitoGamide. b Overview of experimental protocol. Tissue Doppler echocardiography was used to derive c peak e′ and peak a′ velocity, and d e′/a′ ratio. Doppler echocardiography was used to derive e deceleration time. f E/e′ ratio g peak E and peak A wave velocity, and h E/A ratio. i Representative images of Doppler and tissue Doppler echocardiography. Data are presented as mean ± SEM. n = 8–13 per group. *P < 0.05, **P < 0.01, ****P < 0.0001. Two-way ANOVA followed by Tukey’s post hoc test. V, vehicle; MG, MitoGamide; WT, wild type
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50. doi: 10.1016/j.diabres.2017.03.024. - DOI - PubMed
    1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29–34. doi: 10.1016/0002-9149(74)90089-7. - DOI - PubMed
    1. Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol. 2018;71:339–351. doi: 10.1016/j.jacc.2017.11.019. - DOI - PubMed
    1. Gustafsson I, Brendorp B, Seibaek M, Burchardt H, Hildebrandt P, Køber L, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol. 2004;43:771–777. doi: 10.1016/j.jacc.2003.11.024. - DOI - PubMed
    1. Tate M, Grieve DJ, Ritchie RH. Are targeted therapies for diabetic cardiomyopathy on the horizon? Clin Sci (Lond) 2017;131:897–915. doi: 10.1042/CS20160491. - DOI - PubMed

MeSH terms